Menactra is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitis serogroups A, C, Y, and W-135. Menactra is approved for use in individuals 9 months through 55 years of age. Menactra does not prevent N meningitis serogroup B disease.
Menactra is contraindicated in persons who have had a severe allergic reaction (e.g., anaphylaxis) after a previous dose of a meningococcal capsular polysaccharide-, diphtheria toxoid-, or CRM197-containing vaccine, or to any component of the vaccine.
Persons previously diagnosed with Guillain-Barré syndrome (GBS) may be at increased risk of GBS following receipt of Menactra. GBS has been reported in temporal relationship following administration of Menactra. The decision to give Menactra should be based on careful consideration of the potential benefits and risks.
Syncope (fainting) can occur in association with administration of injectable vaccines, including Menactra. Procedures should be in place to prevent falling injury and manage syncopal reactions.
The most common local and systemic adverse reactions to Menactra include pain, redness, and swelling at the injection site and appetite loss (all age groups); induration at the injection site and diarrhea (all age groups except infants); irritability and drowsiness (infants and children); abnormal crying, vomiting, and fever (infants); headache, fatigue, malaise, and arthralgia (adolescents and adults). Other adverse reactions may occur. Vaccination with Menactra may not protect all individuals.